凯西集团中国总裁兼总经理邓浩青：博鳌乐城“先行先试”政策是一场双向奔赴，让“蝴蝶宝贝”有药可医

Core Insights - The article discusses the introduction of the innovative drug FILSUVEZ for treating Epidermolysis Bullosa (EB) in China, marking a significant advancement for patients suffering from this rare genetic skin disease [1][2][3]. Group 1: Drug Introduction and Significance - FILSUVEZ is the first drug approved for treating nutritional deficiency-related (DEB) and junctional (JEB) EB wounds in patients aged six months and older, receiving approvals from EMA and FDA in 2022 and 2023 respectively [2]. - The drug's availability in China is facilitated by the "first trial" policy in the Boao Lecheng International Medical Tourism Pilot Zone, allowing patients to access the treatment sooner [1][2]. - The introduction of FILSUVEZ not only provides a treatment option for EB patients but also establishes a potential pathway for accelerating the registration of innovative drugs in China [3][4]. Group 2: Collaboration and Process - The collaboration between the Casi Group and the Boao Lecheng management involved discussions on the need for innovative products, leading to the successful introduction of FILSUVEZ [2][3]. - A complete process was established for patient selection, medication assessment, and cross-province medical treatment, ensuring safe drug usage for EB patients [2][3]. Group 3: Market Dynamics and Future Strategies - The Boao Lecheng zone has introduced 510 special drugs and devices across 28 clinical disciplines, benefiting over 120,000 patients as of September 2023 [3]. - The Casi Group is initiating the formal registration process for FILSUVEZ in China while maintaining close communication with the National Medical Products Administration [3][4]. - The company aims to leverage real-world data from the Boao Lecheng phase to support future drug registration and insurance access [4]. Group 4: Corporate Strategy and Market Position - Casi Group's strategy includes "China to Global," "Global to China," and "China to China," focusing on local needs and expanding its presence in the rare disease sector [5][6]. - The company has seen a 22% revenue growth in China, positioning it as one of the fastest-growing markets for Casi Group, with aspirations to rank among the top five global markets in the next decade [7].